eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
vol. 41
Review paper

Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review

Hio Fong Leong
Wen-hui Wang
Fen Peng

  1. Department of Dermatology, Peking University Third Hospital, Beijing, China
Adv Dermatol Allergol 2024; XLI (3): 262-269
Online publish date: 2024/06/30
View full text Get citation
Palmoplantar pustulosis (PPP) is a complex inflammatory skin disease. Currently, no standardized treatments exist, and traditional systemic therapies often display limited effectiveness and substantial adverse effects. Biologics, however, have shown potential for enhanced clinical outcomes in psoriasis patients, thereby prompting this investigation into their applicability in PPP treatment.

This study constitutes the first comprehensive review to assess the effectiveness and underlying mechanisms of biologics for PPP.

Material and methods:
We conducted a PubMed search to identify studies on biologics for PPP from 1992 onward. The review focused on assessing the efficacy of biologics targeting cytokines like IL-1, IL-8, IL-17, IL-12/23, IL-36, and TNF-a.

Biologics for PPP are generally less effective than for psoriasis. Secukinumab and guselkumab, IL-17 and IL-23 inhibitors respectively, have shown better results compared to other biologics in trials. However, the effectiveness of other biologics remains uncertain due to limited data.

More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging.


palmoplantar pustulosis, biologics, treatments

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.